• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    10/7/24 4:50:17 PM ET
    $DECA
    Blank Checks
    Finance
    Get the next $DECA alert in real time by email
    SC 13G/A 1 tm2425684d4_sc13ga.htm SC 13G/A

      

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)*

     

    Under the Securities Exchange Act of 1934

     

    Denali Capital Acquisition Corp.

    (Name of Issuer)
     

    Class A

    (Title of Class of Securities)
     

    G6256B106

    (CUSIP Number)
     
    9/30/2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G6256B106    

     

    1 Name of Reporting PersonS.
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
    Calamos Market Neutral Income Fund, a series of Calamos Investment Trust
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
      (a) ¨
    (b) ¨
    3 SEC USE ONLY
     
    4 CITIZENship or place of organization
    Massachusetts, U.S.A.
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5 sole voting power
    0
    6 shared voting power
    0
    7 sole dispositive power

    0

    8 shared dispositive power
    0
    9 aggregate amount beneficially owned by each reporting person
     0%
    10

    check box if the aggregate amount in row (9) excludes certain shares (See Instructions)                 ¨

     

    11 percent of class represented by amount in row (9)
     0%
    12 type of reporting person (See Instructions)
    IV
             

     

     Page 2 of 6 

     

     

    CUSIP No. G6256B106    

     

    Item 1.(a) Name of Issuer

     

    Denali Capital Acquisition Corp.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    437 MADISON AVENUE, 27TH FLOOR,

    NEW YORK, NY, 10022

     

    Item 2.(a)    Name of Person Filing

     

    Calamos Market Neutral Income Fund, a series of Calamos Investment Trust

     

    (b)Address of Principal Business Office or, if none, Residence
       
      2020 Calamos Court
      Naperville, IL 60563

     

    (c)Citizenship

     

    Massachusetts, U.S.A.

     

    (d)Title of Class of Securities

     

    Class A

     

    (e)CUSIP Number

     

    G6256B106

     

    Item 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      (a)   ¨   Broker or dealer registered under section 15 of the Exchange Act.
         
      (b)   ¨   Bank as defined in section 3(a)(6) of the Exchange Act.
         
      (c)   ¨   Insurance company as defined in section 3(a)(19) of the Exchange Act.
         
      (d)   x   Investment company registered under section 8 of the Investment Company Act.
         
      (e)   ¨   An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
         
      (f)   ¨   An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
         
      (g)   ¨   A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
         
      (h)   ¨   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
      (i)   ¨   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act.
         
      (j)   ¨   A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
         
      (k)   ¨   Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     
      Not applicable.

     

     Page 3 of 6 

     

     

    CUSIP No. G6256B106    

     

    Item 4.Ownership.

     

    The following information is provided as of September 30, 2024:

     

    The following sets forth the share ownership as to each of the Reporting Persons:

     

      (a)  Amount beneficially owned: 0%
       
      (b) Percent of class: 0%
       
      (c) Number of shares as to which the person has:

     

      (i) sole power to vote or to direct the vote of:
       
        0 ordinary shares
       
      (ii) shared power to vote or to direct the vote of:
       
        0 ordinary shares
       
      (iii) sole power to dispose or to direct the disposition of:
       
        0 ordinary shares
       
      (iv) shared power to dispose or to direct the disposition of:
       
        0 ordinary shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 4 of 6 

     

     

    CUSIP No. G6256B106    

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 5 of 6 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 7, 2024

     

     

    Calamos Market Neutral Income Fund, a series of Calamos Investment Trust

       
      By: /s/ Susan Schoenberger
      Name: Susan Schoenberger
      Title: Assistant Secretary

     

     Page 6 of 6 

     

     

    Get the next $DECA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DECA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DECA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      12/6/24 4:17:05 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 5:49:50 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 2:35:09 PM ET
      $DECA
      Blank Checks
      Finance

    $DECA
    Financials

    Live finance-specific insights

    See more
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

      As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

      11/6/24 12:24:36 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

      Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

      10/28/24 6:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

      Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

      10/16/24 4:00:00 AM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    SEC Filings

    See more
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/22/25 5:10:19 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

      S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/21/25 5:17:32 PM ET
      $DECA
      Blank Checks
      Finance
    • Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

      4/15/25 9:20:12 PM ET
      $DECA
      Blank Checks
      Finance

    $DECA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

      4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

      9/16/24 10:05:57 AM ET
      $DECA
      Blank Checks
      Finance
    • SEC Form 4 filed by Large owner Xu Jiandong

      4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

      9/16/24 10:01:42 AM ET
      $DECA
      Blank Checks
      Finance

    $DECA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

      5/9/25 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

      4/14/25 4:35:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Capital Acquisition Corp. Announces Adjournment of Extraordinary General Meeting of Shareholders to April 11, 2025 at 10:00 AM ET.

      NEW YORK, NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that the Company's Extraordinary General Meeting of Shareholders (the "Extraordinary General Meeting") was convened on April 10, 2025 at 9:00 a.m. Eastern Time and adjourned as it was deemed advisable to do so in order to provide shareholders of record with additional time to consider the proposals being voted on at the Extraordinary General Meeting as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2025..The Extraordinary General Meeting has been adjourned to Friday, April 11, 2025, at 10

      4/10/25 4:00:00 PM ET
      $DECA
      Blank Checks
      Finance